TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05035667

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT04756154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHG/IPA Surgical skin preparation
Description: Apply topically to the inguinal region for 2 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG/IPA Surgical skin preparation
Description: Apply topically to the inguinal region for 2 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Apply topically to the inguinal region for 2 minutes
Study: NCT03835637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-101
Description: Capsule or oral suspension
Study: NCT02164097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODSH
Study: NCT01234649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR plus placebo
Description: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR plus liraglutide
Description: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)
Study: NCT04192474

Intervention type: DEVICE
Group type: OTHER
Intervention: Flexible cystoscopy
Description: Treatment with the investigational device: Ambu® aScope™ 4 Cysto
Study: NCT04296890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
Study: NCT04663568

Intervention type: DEVICE
Group type: OTHER
Intervention: Levonorgestrel-releasing intrauterine system
Description: Levonorgestrel-releasing intrauterine system will be inserted during the menstrual cycle
Study: NCT01088529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg oral daily for 3 months followed by a prostatectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRHa
Description: LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3 months or 1 injection each month for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRHa
Description: LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3 months or 1 injection each month for 3 months.
Study: NCT04540484

Intervention type: OTHER
Intervention: Screening
Description: Blood test screening for covid

Intervention type: OTHER
Intervention: Screening
Description: Blood test screening for covid
Study: NCT04658186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0599
Description: Drug: UCB0599 Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive UCB0599 in a pre-specified sequence during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0599
Description: Drug: UCB0599 Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive UCB0599 in a pre-specified sequence during the Treatment Period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Pharmaceutical form: Capsules Route of administration: Oral use Participants will receive Placebo in a pre-specified sequence during the Treatment Period.
Study: NCT02210819

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Cohort participants are classified as rivaroxaban patient, if the patient receives initial rivaroxaban VTE treatment. Dosing according to daily clinical routine

Intervention type: DRUG
Intervention: Recommended VTE pharmacological treatments according to international guidelines
Description: Cohort participants are classified as Standard of care patients, if the patient receives recommended VTE pharmacological treatments according to international guidelines, e.g. unfractionated heparin, LMWH, fondaparinux, VKA, if these are also approved pharmacological treatments for VTE in the respective country. Dosing according to daily clinical routine.
Study: NCT03065114

Intervention type: OTHER
Intervention: PGS
Description: chromosome abnormality test from PGS and relationship between embryo development
Study: NCT01535274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspired oxygen fraction / end tidal carbon dioxide
Description: Following induction of anesthesia, FIO2 and minute ventilation will be sequentially adjusted to achieve:~1. FIO2 30% (70% nitrogen), PETCO2 30mmHg - supine position.~2. FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position.~3. FIO2 100%, PETCO2 30mmHg - beach chair position.~4. FIO2 100%, PETCO2 45mmHg - beach chair position.~5. FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspired oxygen fraction / end tidal carbon dioxide
Description: Following induction of anesthesia, FIO2 and minute ventilation will be sequentially adjusted to achieve:~1. FIO2 30% (70% nitrogen), PETCO2 30mmHg - supine position.~2. FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position.~3. FIO2 100%, PETCO2 30mmHg - beach chair position.~4. FIO2 100%, PETCO2 45mmHg - beach chair position.~5. FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position.
Study: NCT02168543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02447835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine is approved for the treatment of schizophrenia and mania associated with bipolar disorder. Olanzapine is a psychotropic agent that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-4methyl-1 piperazinyl-10H-thienol (2,3-b)\[1,5\]benzodiazepine. The molecular formula is C17H20N4S which corresponds to a molecular weight of 312.44.Olanzpine is a yellow crystalline solid which is practically insoluble in water. Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors:5HT2A2C, 5HT6, dopamine 2-4, histamine H1, and adrenergic α-1. In addition olanzapine is an antagonist with moderate affinity for muscarinic M1-5 and 5HT3. The mechanism of action of olanzapine is unknown although it may be mediated through a combination of dopamine and serotonergic type 2 receptors.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine is approved for the treatment of schizophrenia and mania associated with bipolar disorder. Olanzapine is a psychotropic agent that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-4methyl-1 piperazinyl-10H-thienol (2,3-b)\[1,5\]benzodiazepine. The molecular formula is C17H20N4S which corresponds to a molecular weight of 312.44.Olanzpine is a yellow crystalline solid which is practically insoluble in water. Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors:5HT2A2C, 5HT6, dopamine 2-4, histamine H1, and adrenergic α-1. In addition olanzapine is an antagonist with moderate affinity for muscarinic M1-5 and 5HT3. The mechanism of action of olanzapine is unknown although it may be mediated through a combination of dopamine and serotonergic type 2 receptors.
Study: NCT02081456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft Tissue Mobilization
Description: Patients in the STM group received treatment in supine, with their head resting on one pillow and the involved UE positioned in abduction and external rotation to preload the neural structures of the upper limb. Manual pressure was applied to the soft tissues of the upper quadrant in a deep, stroking manner with the intention to improve the mobility of the soft tissues surrounding the pathway of the neural structures of the upper limb as well as any tender or tight tissues. The therapist spent approximately 7 minutes on the neck and scapular region, 4 minutes on the upper arm, and 4 minutes on the forearm and hand. The therapist was allowed to vary the time spent on each region according to his/her assessment of the patient's condition. The procedure lasted a total of 15 minutes.
Study: NCT04624958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib and Rituximab
Description: Zanubrutinb 160mg PO BID d1-28; Rituximab 375mg/m2 iv.drip d1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-DHAOx
Description: Rituximab 375mg/m2 iv.drip d1; Dexamethasone 20mg iv.drip d1-4; Cytarabine 2000mg/m2 (1000mg/m2 for patients aged over 65) iv.drip d2,3 Oxaliplatin 130mg/m2 iv.drip d1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib Maintenance
Description: Zanubrutinb 160mg PO BID.
Study: NCT02081456

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Ultrasound
Description: Patients received therapeutic US applied for a period of 5 minutes to the most painful region of the neck, then a second 5-minute dose at the most painful region of the upper extremity. The US dose was 0.5 w/cm2, with sonation time 50% and frequency 1 MHz.40,52 The patient lay supine with the hand of the involved upper extremity placed on the abdomen and the elbow supported on a pillow. The two US doses and interaction time with the patient lasted a total of 15 minutes in an attempt to have equal patient/therapist contact between the two groups.
Study: NCT02538770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid diagnostics using Anyplex TMII RV16 Detection
Description: Rapid diagnostics using Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR as soon as they are available

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed diagnostics Anyplex TMII RV16 Detection
Description: Delayed diagnostics Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR after one week delay unless specifically solicited
Study: NCT01424436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK933776
Description: 1mg/kg dose group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK933776
Description: 3mg/kg dose group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK933776
Description: 6mg/kg dose group
Study: NCT01154894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aravita including arachidonic acid and docosaheaenoic acid
Description: Nine of 13 Participants were treated with 6 capsules of Aravita per day for 16-week trial, remaining 4 participants aged under 12 years received 3 capsules per day.
Study: NCT01850082

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vein Harvesting Procedures
Description: Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as bridging technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vein Harvesting Procedures
Description: Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as bridging technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH.
Study: NCT04879316

Intervention type: OTHER
Intervention: Resting Energy Expenditure measurement
Description: Resting Energy Expenditure measurement using indirect calorimetry
Study: NCT00641758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pycnogenol
Description: Pycnogenol 100mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 100mg twice daily
Study: NCT04453215

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: GaAlAs semiconductor diode laser device
Description: low-level laser therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GaAlAs semiconductor diode laser device
Description: low-level laser therapy
Study: NCT01356667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DARTNA
Description: 3-hour protocol provided 2x/week over 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-As-Usual
Description: Participants will receive typical substance abuse behavior treatment interventions typically provided to patients including individual counseling, group therapy, and standard culturally-based interventions.
Study: NCT01317290

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 PUFA free olive oil
Description: negative control

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: linseed oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: linseed oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: linseed oil
Study: NCT04107896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: Cap silodosin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Cap tamsulosin
Study: NCT01564745

Intervention type: OTHER
Group type: OTHER
Intervention: Functional respiratory evaluation
Description: Each enrolled patients has a pulmonary function test before and after extubation, and repeatedly at D1, D3, D5 (if they are always hospitalized)
Study: NCT04903834

Intervention type: DIAGNOSTIC_TEST
Intervention: Soton hyperinflammation score
Description: Score for hyperinflammation defined by blood parameters and other physiological measurements

Intervention type: DIAGNOSTIC_TEST
Intervention: Soton hyperinflammation score
Description: Score for hyperinflammation defined by blood parameters and other physiological measurements

Intervention type: DIAGNOSTIC_TEST
Intervention: HScore
Description: Score for secondary haemophagocytic lymphohistiocytosis validated in prior publications

Intervention type: DIAGNOSTIC_TEST
Intervention: HScore
Description: Score for secondary haemophagocytic lymphohistiocytosis validated in prior publications
Study: NCT03344822

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: radioactive tracer for PET-CT (68Ga-PSMA-11)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-Choline PET-CT
Description: radioactive tracer for PET-CT (18F-Choline PET-CT)
Study: NCT04652141

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: AsthmaTuner
Description: AsthmaTuner consists of a treatment-adjusting algorithm that gives patient immediate feedback on the status of symptom control (i.e. controlled, partly controlled or uncontrolled) and a treatment recommendation with an image of the correct inhaler or other type of medication and the dose based on lung function (FEV1) and symptom scores (0-4 points).
Study: NCT00747318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKP FlutiForm HFA pMDI
Description: Each subject will receive SKP FlutiForm HFA pMDI 250/10 microgram twice daily for 60 weeks (two actuations of SKP FlutiForm HFA pMDI 125/5 microgram/actuation) for a total daily dose of 500 microgram fluticasone propionate and 20 microgram formoterol fumarate.
Study: NCT02841267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF 06252616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF 06252616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF 06252616
Study: NCT02107248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep position: no restrictions
Description: during the first eight weeks after total hip replacement following a posterolateral surgical approach

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep position: supine
Description: during the first eight weeks after total hip replacement following a posterolateral surgical approach
Study: NCT01468532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pasireotide
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study: NCT03857412

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Capsular polishing
Description: Capsular polishing taking place during cataract surgery

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non capsular polishing
Description: No capsular polishing taking place during cataract surgery
Study: NCT02572843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 (anti-PD-L1)
Description: fixed dosing 750 mg
Study: NCT02161861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cFFE increase the fusiogenic capacities of a gamete
Study: NCT00412035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A injection
Description: 10 units per kilo to maximum of 400 units

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline injection
Description: 10 units per kilo to maximum of 400 units
Study: NCT03044262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive strip
Description: This is a standard adhesive strip (hydrocolloid) that is part of an ostomy device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New adhesive strip
Description: This is a newly developed adhesive strip that in the future might be part of an ostomy device
Study: NCT00853281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hammocks with LLIN
Description: Locally-made hammocks covered with long lasting insecticidal nel (LLIN)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard vector control measures
Description: Insectice-treated net
Study: NCT03791385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Picture Exchange Communication System (PECS)
Description: A communication system frequently used with non-verbal children with autism spectrum disorders (ASD) that uses a series of pictures that describe how a certain activity is done, in our case showing a structured method and technique for teeth brushing.
Study: NCT03806868

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: voucher for ordering foods (ONLY omega-3 rich foods)
Description: A voucher will be provided weekly (4 times) for ordering only omega-3 rich foods. Groceries will be delivered to participants' home weekly.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: voucher for ordering foods in general (any type of foods)
Description: A voucher will be provided weekly (4 times) for ordering any type of food. Groceries will be delivered to participants' home weekly.
Study: NCT00914290

Intervention type: DRUG
Group type: OTHER
Intervention: IPX056
Description: IPX056 ER capsule containing 10 mg baclofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPX056
Description: IPX056 ER capsule containing 10 mg baclofen

Intervention type: DRUG
Group type: OTHER
Intervention: Baclofen IR
Description: Encapsulated baclofen tablet 5 mg per capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen IR
Description: Encapsulated baclofen tablet 5 mg per capsule

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IPX056
Description: Placebo capsule for IPX056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo IPX056
Description: Placebo capsule for IPX056

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IR
Description: Placebo encapsulated baclofen placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo IR
Description: Placebo encapsulated baclofen placebo tablet
Study: NCT02380508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG SSI
Description: Intradermal injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No vaccination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG Sii
Description: intradermal injection
Study: NCT02146222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGFR/PDGFR dual kinase inhibitor X-82
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGFR/PDGFR dual kinase inhibitor X-82
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluorine F 18 fluorothymidine
Description: Undergo FLT PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluorine F 18 fluorothymidine
Description: Undergo FLT PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography/computed tomography
Description: Undergo FLT PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography/computed tomography
Description: Undergo FLT PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01548859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0.2 mg/kg/saat continuous infusion of midazolam received during anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: end tidal concentration of % 0,5-8